169 related articles for article (PubMed ID: 31620896)
21. Recurrence risk and prognostic parameters in stage I rectal cancers.
Cihan S; Kucukoner M; Ozdemir N; Dane F; Sendur MA; Yazilitas D; Urakci Z; Durnali A; Yuksel S; Aksoy S; Colak D; Seker MM; Taskoylu BY; Oguz A; Isikdogan A; Zengin N
Asian Pac J Cancer Prev; 2014; 15(13):5337-41. PubMed ID: 25040998
[TBL] [Abstract][Full Text] [Related]
22. Does Adjuvant Chemotherapy for Locally Advanced Resectable Rectal Cancer treated with Neoadjuvant Chemoradiotherapy have an impact on survival? A Single Moroccan Institute Retrospective Study.
Seddik Y; Brahmi SA; Afqir S
Gulf J Oncolog; 2019 May; 1(30):29-32. PubMed ID: 31242979
[TBL] [Abstract][Full Text] [Related]
23. Recurrence rates and prognostic factors in ypN0 rectal cancer after neoadjuvant chemoradiation and total mesorectal excision.
Govindarajan A; Reidy D; Weiser MR; Paty PB; Temple LK; Guillem JG; Saltz LB; Wong WD; Nash GM
Ann Surg Oncol; 2011 Dec; 18(13):3666-72. PubMed ID: 21590450
[TBL] [Abstract][Full Text] [Related]
24. [Evaluation of progression-free survival for locally advanced rectal cancer by MRI after neoadjuvant chemoradiotherapy and total mesorectal excision].
Zhang JX; Yang Z; Fan P; Zhang JJ; Xin L; Hou LN; Du XS; Yang XT
Zhonghua Zhong Liu Za Zhi; 2018 Feb; 40(2):121-126. PubMed ID: 29502372
[No Abstract] [Full Text] [Related]
25. Optimal treatment strategy for rectal cancer based on the risk factors for recurrence patterns.
Yamamoto T; Kawada K; Hida K; Ganeko R; Inamoto S; Yoshitomi M; Watanabe T; Sakai Y
Int J Clin Oncol; 2019 Jun; 24(6):677-685. PubMed ID: 30721379
[TBL] [Abstract][Full Text] [Related]
26. The prognostic impact of preoperative blood monocyte count in pathological T3N0M0 rectal cancer without neoadjuvant chemoradiotherapy.
Zhang LN; Xiao W; OuYang PY; You K; Zeng ZF; Ding PR; Pan ZZ; Xu RH; Gao YH
Tumour Biol; 2015 Sep; 36(10):8213-9. PubMed ID: 25994571
[TBL] [Abstract][Full Text] [Related]
27. The potential predictive value of tumor budding for neoadjuvant chemoradiotherapy response in locally advanced rectal cancer.
Jäger T; Neureiter D; Fallaha M; Schredl P; Kiesslich T; Urbas R; Klieser E; Holzinger J; Sedlmayer F; Emmanuel K; Dinnewitzer A
Strahlenther Onkol; 2018 Nov; 194(11):991-1006. PubMed ID: 30069738
[TBL] [Abstract][Full Text] [Related]
28. Local recurrence after five years is associated with preoperative chemoradiotherapy treatment in patients diagnosed with stage II and III rectal cancer.
Marin G; Suárez J; Vera R; Balén E; Viudez A; Mata E
Int J Surg; 2017 Aug; 44():15-20. PubMed ID: 28583894
[TBL] [Abstract][Full Text] [Related]
29. Outcomes of neoadjuvant chemoradiotherapy in Japanese locally advanced rectal carcinoma patients.
Tokuhara K; Ueyama Y; Nakatani K; Yoshioka K; Kon M
World J Surg Oncol; 2016 Apr; 14():136. PubMed ID: 27129578
[TBL] [Abstract][Full Text] [Related]
30. The effects of chemoradiotherapy on recurrence and survival in locally advanced rectal cancers with curative total mesorectal excision: a prospective, nonrandomized study.
Akgun E; Ozkok S; Tekin M; Yoldas T; Caliskan C; Kose T; Karabulut B; Sezak M; Elmas N; Ozutemiz O
World J Surg Oncol; 2017 Nov; 15(1):205. PubMed ID: 29166925
[TBL] [Abstract][Full Text] [Related]
31. [Efficacy analysis of neoadjuvant chemoradiotherapy combined with total pelvic exenteration in the treatment of primary T4b rectal cancer].
Wu T; Wen L; Zhang J; Wu Y; Jiang Y; Chen G; Wang X; Huang S; Wan Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Jan; 22(1):59-65. PubMed ID: 30703795
[TBL] [Abstract][Full Text] [Related]
32. The role of tissue diagnosis prior to neoadjuvant chemoradiotherapy for locally advanced rectal cancer.
Daniel ES; Gibbs P; Guerrieri M; Faragher I
Colorectal Dis; 2014 Oct; 16(10):783-7. PubMed ID: 24786681
[TBL] [Abstract][Full Text] [Related]
33. Nonoperative management after neoadjuvant therapy for rectal cancer: A single institution experience over 5 years.
Strode M; Shah R; Boland PM; Francescutti VA; Mangieri CW; Attwood K; Nurkin SJ
Surg Oncol; 2019 Mar; 28():116-120. PubMed ID: 30851884
[TBL] [Abstract][Full Text] [Related]
34. Predicting pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer using 18FDG-PET/CT.
Shanmugan S; Arrangoiz R; Nitzkorski JR; Yu JQ; Li T; Cooper H; Konski A; Farma JM; Sigurdson ER
Ann Surg Oncol; 2012 Jul; 19(7):2178-85. PubMed ID: 22395978
[TBL] [Abstract][Full Text] [Related]
35. [An initial exploration of the application of transanal endoscopic microsurgery in rectal cancer patients with clinical complete response after neoadjuvant chemoradiotherapy].
Xue XQ; Zhou JL; Lin GL; Bai XS; Xiao Y; Wu B; Qiu HZ
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Jun; 22(6):560-565. PubMed ID: 31238635
[No Abstract] [Full Text] [Related]
36. Rsf-1 expression in rectal cancer: with special emphasis on the independent prognostic value after neoadjuvant chemoradiation.
Lin CY; Tian YF; Wu LC; Chen LT; Lin LC; Hsing CH; Lee SW; Sheu MJ; Lee HH; Wang YH; Shiue YL; Wu WR; Huang HY; Hsu HP; Li CF; Chen SH
J Clin Pathol; 2012 Aug; 65(8):687-92. PubMed ID: 22569540
[TBL] [Abstract][Full Text] [Related]
37. [Efficacy of cetuximab combined with chemotherapy for patients with advanced colorectal cancer and unclear K-ras status].
Guo GF; Xia LP; Qiu HJ; Xu RH; Zhang B; Jiang WQ; Zhou FF; Wang F
Zhonghua Zhong Liu Za Zhi; 2010 Oct; 32(10):777-81. PubMed ID: 21163071
[TBL] [Abstract][Full Text] [Related]
38. Outcomes in locally advanced rectal cancer with highly selective preoperative chemoradiotherapy.
Williamson JS; Jones HG; Davies M; Evans MD; Hatcher O; Beynon J; Harris DA;
Br J Surg; 2014 Sep; 101(10):1290-8. PubMed ID: 24924947
[TBL] [Abstract][Full Text] [Related]
39. Can pathological complete response in the primary tumour following pre-operative pelvic chemoradiotherapy for T3-T4 rectal cancer predict for sterilisation of pelvic lymph nodes, a low risk of local recurrence and the appropriateness of local excision?
Hughes R; Glynne-Jones R; Grainger J; Richman P; Makris A; Harrison M; Ashford R; Harrison RA; Livingstone JI; McDonald PJ; Meyrick Thomas J; Mitchell IC; Northover JM; Phillips R; Wallace M; Windsor A; Novell JR
Int J Colorectal Dis; 2006 Jan; 21(1):11-7. PubMed ID: 15864605
[TBL] [Abstract][Full Text] [Related]
40. CAPIRI-IMRT: a phase II study of concurrent capecitabine and irinotecan with intensity-modulated radiation therapy for the treatment of recurrent rectal cancer.
Cai G; Zhu J; Palmer JD; Xu Y; Hu W; Gu W; Cai S; Zhang Z
Radiat Oncol; 2015 Feb; 10():57. PubMed ID: 25889149
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
